Both of these players are leaders in their fields.

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

(Bloomberg) -- The stock market’s recent wipeout has pushed a quarter of biotechnology stocks to trade below their cash holdings. That’s left bargain-hunters with a choice: Buy the dip or sit this one ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

TRINITY BIOTECH ($TRIB) is expected to release its quarterly earnings data on Thursday, May 22nd before market open, per Finnhub. Analysts are expecting revenue of ...

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Jones Trading in a report released on Friday,Benzinga reports. Several other equities ...

SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of ...

(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by ...

Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a ...